• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用机器学习从大规模电子健康记录中识别阿尔茨海默病的进展亚表型。

Identifying progression subphenotypes of Alzheimer's disease from large-scale electronic health records with machine learning.

作者信息

Zhou Manqi, Tang Alice S, Zhang Hao, Xu Zhenxing, Ke Alison M C, Su Chang, Huang Yu, Mantyh William G, Jaffee Michael S, Rankin Katherine P, DeKosky Steven T, Zhou Jiayu, Guo Yi, Bian Jiang, Sirota Marina, Wang Fei

机构信息

Department of Computational Biology, Cornell University, Ithaca, NY 14853, USA.

Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA; Graduate Program in Bioengineering, University of California, San Francisco and University of California, Berkeley, San Francisco and Berkeley, CA 94143, USA.

出版信息

J Biomed Inform. 2025 May;165:104820. doi: 10.1016/j.jbi.2025.104820. Epub 2025 Apr 1.

DOI:10.1016/j.jbi.2025.104820
PMID:40180206
Abstract

OBJECTIVE

Identification of clinically meaningful subphenotypes of disease progression can enhance the understanding of disease heterogeneity and underlying pathophysiology. In this study, we propose a machine learning framework to identify subphenotypes of Alzheimer's disease progression based on longitudinal real-world patient records.

METHODS

The framework, dynaPhenoM, extracts coherent clinical topics across patient visits and employs a time-aware latent class analysis to characterize subphenotypes. We validated dynaPhenoM using three patient databases with a total of 3952 AD patients across the United States, demonstrating its effectiveness in revealing mild cognitive impairment (MCI) progression to AD.

RESULTS

Our study identified five subphenotypes associated with distinct organ systems for disease progression from MCI to AD, including common subtypes across cohorts-respiratory, musculoskeletal, cardiovascular, and endocrine/metabolic-as well as a cohort-specific digestive subtype.

CONCLUSION

Our study unravels the complexity and heterogeneity of the progression from MCI to AD. These findings highlight disease progression heterogeneity and can inform both diagnostic and therapeutic strategies, thereby advancing precision medicine for Alzheimer's disease.

摘要

目的

识别具有临床意义的疾病进展亚表型能够增进对疾病异质性和潜在病理生理学的理解。在本研究中,我们提出了一个机器学习框架,用于基于纵向真实世界患者记录识别阿尔茨海默病进展的亚表型。

方法

该框架dynaPhenoM提取患者就诊期间连贯的临床主题,并采用时间感知潜在类别分析来表征亚表型。我们使用三个患者数据库对dynaPhenoM进行了验证,这些数据库共有来自美国的3952名AD患者,证明了其在揭示轻度认知障碍(MCI)向AD进展方面的有效性。

结果

我们的研究确定了从MCI到AD的疾病进展中与不同器官系统相关的五种亚表型,包括各队列共有的亚型——呼吸、肌肉骨骼、心血管和内分泌/代谢——以及特定队列的消化亚型。

结论

我们的研究揭示了从MCI到AD进展的复杂性和异质性。这些发现突出了疾病进展的异质性,并可为诊断和治疗策略提供信息,从而推动阿尔茨海默病的精准医学发展。

相似文献

1
Identifying progression subphenotypes of Alzheimer's disease from large-scale electronic health records with machine learning.利用机器学习从大规模电子健康记录中识别阿尔茨海默病的进展亚表型。
J Biomed Inform. 2025 May;165:104820. doi: 10.1016/j.jbi.2025.104820. Epub 2025 Apr 1.
2
Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage.预测认知衰退:深度学习揭示轻度认知障碍前阶段大脑的细微变化。
J Prev Alzheimers Dis. 2025 May;12(5):100079. doi: 10.1016/j.tjpad.2025.100079. Epub 2025 Feb 6.
3
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
4
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
5
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
6
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.
7
Vitamin E for Alzheimer's dementia and mild cognitive impairment.维生素E用于治疗阿尔茨海默病性痴呆和轻度认知障碍。
Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD002854. doi: 10.1002/14651858.CD002854.pub4.
8
Vitamin E for Alzheimer's dementia and mild cognitive impairment.维生素E用于治疗阿尔茨海默病性痴呆和轻度认知障碍。
Cochrane Database Syst Rev. 2017 Apr 18;4(4):CD002854. doi: 10.1002/14651858.CD002854.pub5.
9
Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).用于检测轻度认知障碍(MCI)患者中阿尔茨海默病及其他痴呆症的简易精神状态检查表(MMSE)。
Cochrane Database Syst Rev. 2015 Mar 5;2015(3):CD010783. doi: 10.1002/14651858.CD010783.pub2.
10
(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).(11)使用C-PIB-PET对轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆进行早期诊断。
Cochrane Database Syst Rev. 2014 Jul 23;2014(7):CD010386. doi: 10.1002/14651858.CD010386.pub2.

本文引用的文献

1
Structured Counselling and Regular Telephonic follow up to improve Referral flow and compliance in Nepal for Diabetic Retinopathy(SCREEN-D Study): a randomised controlled trial.结构咨询和定期电话随访以改善尼泊尔糖尿病视网膜病变的转诊流程和依从性(SCREEN-D 研究):一项随机对照试验。
BMC Health Serv Res. 2024 Feb 10;24(1):188. doi: 10.1186/s12913-024-10647-3.
2
Identification of Outcome-Oriented Progression Subtypes from Mild Cognitive Impairment to Alzheimer's Disease Using Electronic Health Records.基于电子健康记录的轻度认知障碍向阿尔茨海默病进展的结局导向亚组识别。
AMIA Annu Symp Proc. 2024 Jan 11;2023:764-773. eCollection 2023.
3
Autonomous artificial intelligence increases screening and follow-up for diabetic retinopathy in youth: the ACCESS randomized control trial.
自主人工智能增加青少年糖尿病视网膜病变的筛查和随访:ACCESS 随机对照试验。
Nat Commun. 2024 Jan 11;15(1):421. doi: 10.1038/s41467-023-44676-z.
4
Cardiovascular Disease and Alzheimer's Disease: The Heart-Brain Axis.心血管疾病与阿尔茨海默病:心脑轴。
J Am Heart Assoc. 2023 Nov 7;12(21):e030780. doi: 10.1161/JAHA.123.030780. Epub 2023 Nov 6.
5
Risk of dementia or cognitive impairment in COPD patients: A meta-analysis of cohort studies.慢性阻塞性肺疾病(COPD)患者患痴呆症或认知障碍的风险:队列研究的荟萃分析
Front Aging Neurosci. 2022 Sep 9;14:962562. doi: 10.3389/fnagi.2022.962562. eCollection 2022.
6
Gastrointestinal Changes and Alzheimer's Disease.胃肠道变化与阿尔茨海默病。
Curr Alzheimer Res. 2022;19(5):335-350. doi: 10.2174/1567205019666220617121255.
7
Anxiety and depression in Alzheimer's disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline.阿尔茨海默病中的焦虑和抑郁:发病机制及与认知衰退关系的系统综述。
Neurol Sci. 2022 Jul;43(7):4107-4124. doi: 10.1007/s10072-022-06068-x. Epub 2022 Apr 23.
8
Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration.阿尔茨海默病的眼部观察:眼部改变与神经退行性变。
Int J Mol Sci. 2022 Feb 24;23(5):2486. doi: 10.3390/ijms23052486.
9
A Bayesian perspective on Biogen's aducanumab trial.贝叶斯视角下百健公司的 aducanumab 试验
Alzheimers Dement. 2022 Nov;18(11):2341-2351. doi: 10.1002/alz.12615. Epub 2022 Mar 2.
10
Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.阿尔茨海默病诊断和进展率的异质性:对治疗试验的影响。
Neurotherapeutics. 2022 Jan;19(1):8-25. doi: 10.1007/s13311-022-01185-z. Epub 2022 Jan 27.